Sunvozertinib Tablets were conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions, who have experienced disease progression during or after platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy.236–246 Approximately 2% of NSCLC patients carry EGFR exon 20 insertion mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.